Detalhe da pesquisa
1.
Melflufen plus dexamethasone in relapsed/refractory multiple myeloma: long-term survival follow-up from the Phase II study O-12-M1.
Br J Haematol
; 193(6): 1105-1109, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-33403663
2.
Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Br J Haematol
; 184(4): 536-546, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30460684
3.
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Eur J Haematol
; 102(6): 494-503, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30943323
4.
Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
Br J Haematol
; 182(2): 231-244, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29938772
5.
A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.
Haematologica
; 103(9): 1518-1526, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29954932
6.
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
Lancet Oncol
; 13(7): 716-23, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22677155
7.
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Lancet Haematol
; 9(2): e98-e110, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-35032434
8.
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
J Clin Oncol
; 39(7): 757-767, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33296242
9.
Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
Lancet Haematol
; 7(5): e395-e407, 2020 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-32213344
10.
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Eur J Cancer
; 106: 89-98, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30471652
11.
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Blood
; 108(4): 1158-64, 2006 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16609064
12.
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.
J Clin Oncol
; 24(34): 5343-9, 2006 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17088571